How pyruvate affects the development of myofibroblasts in myelofibrosis.
The impact of pyruvate metabolic fate in myofibroblast differentiation in myelofibrosis.
This study is looking at how changing the way certain cells in your bone marrow use energy might help stop the scarring that happens in myelofibrosis, with the hope of finding new treatments that could improve your blood cell production and ease your symptoms.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11065017 on NIH RePORTER |
What this research studies
This research investigates the role of pyruvate metabolism in the differentiation of myofibroblasts, which are cells that contribute to the scarring of bone marrow in myelofibrosis. The study aims to understand how inhibiting lactate export from fibroblasts can prevent the transformation into myofibroblasts, potentially reversing fibrosis and improving blood cell production. By analyzing gene expression and signaling pathways, the research seeks to identify new treatment strategies that could alter the disease's progression and alleviate symptoms for patients. The approach involves pharmacological interventions targeting specific transporters involved in lactate metabolism.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myelofibrosis who are experiencing symptoms related to bone marrow scarring.
Not a fit: Patients with other types of blood disorders or those not diagnosed with myelofibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively reverse fibrosis and improve blood cell production in patients with myelofibrosis.
How similar studies have performed: While there has been some exploration of metabolic interventions in fibrosis, this specific approach targeting lactate export in myelofibrosis is relatively novel and untested.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Krah, Nathan Michael — University of Utah
- Study coordinator: Krah, Nathan Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.